News · 26 weeks26-60%
2026-03-012026-08-23
Mix1090d
- Earnings4(40%)
- SEC Filings3(30%)
- Insider3(30%)
Latest news
25 items- SECPrecipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio Announces Q2-2026 Financial ResultsNEW HAVEN, Conn., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the second quarter that ended June 30, 2026. Below are some of the key financial performance metrics for the Company. For additional results please see the Company’s Form 10-Q which was filed today. Revenue – $7.0M vs. $6.7M in Q1-2026, and up 22% YoY from $5.7M in Q2-2025. This comprised of $6.1M in pathology revenue (up from $6.0M in Q1) and $0.9M in product revenue (up from $0.66M in Q1).Adjusted EBITDA – $0.4M vs. $(0.2)M in Q1-2026. The change was driven by increased revenues of $0.3 million and a decrease in stock based compensation
- SECPrecipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio Announces Q2-2026 Shareholder Update CallNEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. "We are excited to share our upcoming results for Q2. The team continues to make solid progress in adding customers, expanding our pipeline, and growing the business, which will be reflected in our numbers," said Ilan Danieli, CEO. This call will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management
- INSIDERDirector Valauri Christina Rizopoulos was granted 108 shares, increasing direct ownership by 2% to 5,628 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Cossman Jeffrey was granted 416 shares, increasing direct ownership by 3% to 16,549 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Cohen David Seth was granted 520 shares, increasing direct ownership by 0.95% to 55,199 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- SECPrecipio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders MeetingNEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting. In order to ensure that there is a quorum required for the shareholders' meeting that is scheduled to take place tomorrow, June 15, 2026, at 10 a.m. Eastern Time. At the time of this press release, approximately 42% of shares have been voted. For the company to hold the shareholder meeting, a minimum of 50% of shares must be voted. If the Company does not receive suf
- PRPrecipio to Present at the Planet MicroCap Las VegasNEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion. "We're excited to participate in the Planet MicroCap conference and are looking forward to meeting with many of our existing, as well as new potential shareholders," said Ilan Danieli, CEO. "As a profitable company that is looking to raise awareness rather than raise capital, th
- INSIDERDirector Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- PRPrecipio Announces Q1 2026 Financial ResultsNEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn
- SECSEC Form 10-Q filed by Precipio Inc.10-Q - Precipio, Inc. (0001043961) (Filer)
- PRManagement team's 2025 market-based Options have vestedNEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted. As proposed by the Company's Compensation Committee in late 2024, rather than the standard 4-year time-based vesting period, management was offered and agreed to a market-based vesting structure whereby the options fully vest once the Company's share price exceeds a 10-day VWAP of $30.30. At the time of the grant, the share price and the options strike price w
- SECPrecipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio Announces Q1-2026 Shareholder Update CallNEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company's current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. As part of Precipio's ongoing commitment to transparency and shareholder engagement, this call will be the first time the Company will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management looks forward to addressing investor questions and providing additional insight into the Company's performance, strat
- SECSEC Form DEFA14A filed by Precipio Inc.DEFA14A - Precipio, Inc. (0001043961) (Filer)
- SECSEC Form DEF 14A filed by Precipio Inc.DEF 14A - Precipio, Inc. (0001043961) (Filer)
- INSIDERSEC Form 4 filed by Valauri Christina Rizopoulos4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Cossman Jeffrey4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Cohen David Seth4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Sabet Ahmed Zaki4 - Precipio, Inc. (0001043961) (Issuer)
- SECSEC Form 10-K filed by Precipio Inc.10-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio Announces Q4 and year-end 2025 Shareholder Update CallNEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be
PRPO FAQ
5 questionsWhat does Precipio Inc. do?
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The...Where does PRPO stock trade?
Precipio Inc. (PRPO) is listed on NASDAQ.What sector and industry is PRPO in?
Precipio Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.What companies are similar to PRPO?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare PRPO side-by-side with any of them on Quantisnow.How can I track PRPO on Quantisnow?
Quantisnow aggregates Precipio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRPO to receive live email and push alerts on every new disclosure.